First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report results.

Novo's price cuts lifted Wegovy and Ozempic demand while cheaper GLP-1 therapies expanded India's obesity-drug market.

Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly.

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o

If you are wondering whether Novo Nordisk stock is attractively priced right now, the key is to understand what the recent share price is actually implying about future expectations. The stock last closed at US$45.80, with recent returns of 8.5% over 7 days and 24.1% over 30 days, but a 27.0% decline over 1 year and a 42.7% decline over 3 years. These moves have come alongside ongoing attention on Novo Nordisk's role in pharmaceuticals and biotech, including its position in treatments that...

Novo Nordisk (CPSE:NOVO B) shocked the market with first quarter 2026 results, as its new oral Wegovy weight loss pill quickly surpassed 2 million US prescriptions and prompted a higher full year outlook. See our latest analysis for Novo Nordisk. The strong first quarter has triggered a sharp rebound in sentiment, with a 25.69% 1 month share price return and 8.54% 7 day gain. However, the year to date share price return of 10.52% and 1 year total shareholder return of 27.91% still point to a...

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Amazon will offer same-day delivery for Novo Nordisk's Ozempic pill.